Compugen (CGEN) Return on Capital Employed (2009 - 2026)
Compugen (CGEN) posted quarterly Return on Capital Employed of 24.73% for Q1 2026, up 4064.0% year-over-year from 0.59% in Q1 2025, and down 17.39% on a QoQ basis from 29.94% in Q4 2025.
Compugen (CGEN) Return on Capital Employed (2009 - 2026) Analysis & Trends
Compugen has reported Return on Capital Employed for 18 years, with the latest figure at 24.73% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 24.73%, up 4064.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 24.73% (up 4064.0% YoY), and the FY2025 annual result was 27.67%, up 4286.0% from the prior year.
- Return on Capital Employed retreated to 24.73% in Q1 2026, from 29.94% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 29.94% in Q4 2025 and troughed at 55.69% in Q3 2023.
- A 5-year average of 9.98% and a median of 15.03% in 2024 frame the typical range for Return on Capital Employed.
- The widest annual swing landed in 2023, when Return on Capital Employed slumped 5532 bps; it then surged 6756 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 3.67% in 2022, then sank by 619 bps to 19.05% in 2023, then advanced by 21 bps to 15.03% in 2024, then soared by 299 bps to 29.94% in 2025, then fell by 17 bps to 24.73% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 24.73% in Q1 2026, 29.94% in Q4 2025, and 39.32% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Compugen | 227.88 Mn | 136.13 Mn | 352,000.00 | 24.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.73% |
| Dec 31, 2025 | 29.94% |
| Sep 30, 2025 | -39.32% |
| Jun 30, 2025 | -21.91% |
| Mar 31, 2025 | -15.91% |
| Dec 31, 2024 | -15.03% |
| Sep 30, 2024 | 11.87% |
| Jun 30, 2024 | -5.22% |
| Mar 31, 2024 | -15.75% |
| Dec 31, 2023 | -19.05% |
| Sep 30, 2023 | -55.69% |
| Jun 30, 2023 | -51.64% |
| Mar 31, 2023 | 29.23% |
| Dec 31, 2022 | 3.67% |
| Sep 30, 2022 | -2.37% |
| Jun 30, 2022 | 3.68% |
| Mar 31, 2022 | -30.96% |
| Dec 31, 2021 | -31.81% |
| Sep 30, 2021 | -32.94% |
| Jun 30, 2021 | -31.96% |